Immix Biopharma Inc (IMMX) Stock Price, Quote & News

Company Profile

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was in...

Industry: Biotechnology

Sector: Healthcare

Phone: 310 651 8041

Website: www.immixbio.com

Address:

11400 West Olympic Boulevard, Suite 200, Los Angeles, United States

Dingalingading Jul. 29 at 8:01 PM

$IMMX

0 · Reply

keebs107 Jul. 29 at 4:19 PM

$IMMX

0 · Reply

ruck_my_life Jul. 29 at 9:00 AM

$IMMX Interesting. .

0 · Reply

keebs107 Jul. 28 at 6:42 PM

$IMMX

0 · Reply

RayIngersoll776 Jul. 28 at 3:01 PM

$IMMX works in oncology, but AITX is the one drawing eyes with a Palantir-level growth rate at an Apple-level valuation.

0 · Reply

keebs107 Jul. 24 at 7:29 PM

$IMMX

0 · Reply

PMtrader_92 Jul. 24 at 6:03 PM

$IMMX 🖕

0 · Reply

Dingalingading Jul. 24 at 1:05 PM

$IMMX 🎵🎶 A ponytail can get you tail but keep it out of my Mai Tai. A few cocktails, it never fails, they going to get ya feeling really Sky High. Ponytails, cocktails, ponytails, cocktails, two things that will always rock... But word to all you males,.... don't ever lose those tails, ..... Cuz then you'll just have Pony cock! 🎵🎶

0 · Reply

Stocks4thought Jul. 23 at 6:11 PM

$IMMX Super pent up overhang- thought we'd erased it- but there you saw its exhausting $3.20 going to > $4 now- in about 3 weeks or less. $SLNO

0 · Reply

keebs107 Jul. 23 at 6:04 PM

$IMMX

0 · Reply

Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion

$Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis$

Jul 7, 2025, 9:35 AM EDT - 25 days ago

Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis

Jun 6, 2025, 9:39 AM EDT - 2 months ago

Immix Biopharma Attends FDA CEO Forum in Washington DC

$Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis$

Jun 3, 2025, 2:55 PM EDT - 2 months ago

Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

$Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2$

May 23, 2025, 9:05 AM EDT - 2 months ago

Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2

$Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis$

May 22, 2025, 4:02 PM EDT - 2 months ago

Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

$Immix Biopharma to Host KOL Event to Discuss NXC-201 Clinical Data Presented at ASCO 2025 in relapsed/refractory AL Amyloidosis$

May 21, 2025, 4:03 PM EDT - 2 months ago

Immix Biopharma to Host KOL Event to Discuss NXC-201 Clinical Data Presented at ASCO 2025 in relapsed/refractory AL Amyloidosis

Apr 23, 2025, 10:04 AM EDT - 3 months ago

Immix Biopharma's NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025

$Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis$

Feb 10, 2025, 9:35 AM EST - 6 months ago

Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis

Jan 7, 2025, 9:34 AM EST - 7 months ago

Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T

$Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis$

Dec 19, 2024, 9:35 AM EST - 8 months ago

Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis

$Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis$

Dec 16, 2024, 9:48 AM EST - 8 months ago

Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis

$Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024$

Dec 10, 2024, 9:39 AM EST - 8 months ago

Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024

Dec 9, 2024, 9:33 AM EST - 8 months ago

Immix Biopharma to Host Conference Call for Investors, Analysts and Members of the Media

$Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients$

Nov 25, 2024, 9:32 AM EST - 8 months ago

Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients

Oct 2, 2024, 9:32 AM EDT - 10 months ago

Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2

Sep 19, 2024, 9:31 AM EDT - 11 months ago

Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board

$Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2$

Aug 28, 2024, 9:32 AM EDT - 1 year ago

Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2

Jul 25, 2024, 9:36 PM EDT - 1 year ago

California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)

Jul 8, 2024, 9:31 AM EDT - 1 year ago

Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201

Jun 17, 2024, 9:35 AM EDT - 1 year ago

Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum

$Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation$

May 10, 2024, 9:35 AM EDT - 1 year ago

Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation

Apr 29, 2024, 9:39 AM EDT - 1 year ago

Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma

Apr 18, 2024, 9:32 AM EDT - 1 year ago

Immix Biopharma on Track to Dose NXC-201 Patients in United States

Apr 15, 2024, 9:36 AM EDT - 1 year ago

Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

Mar 20, 2024, 9:46 AM EDT - 1 year ago

Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial

Mar 5, 2024, 9:35 AM EST - 1 year ago

Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative

Feb 21, 2024, 9:31 AM EST - 1 year ago

Immix Biopharma 12 Month Review Progress Update

Feb 8, 2024, 4:45 PM EST - 1 year ago

Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock

Feb 7, 2024, 9:37 AM EST - 1 year ago

Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis

Feb 5, 2024, 10:30 PM EST - 1 year ago

Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock

Feb 5, 2024, 3:20 PM EST - 1 year ago

Immix Biopharma Announces Proposed Public Offering of Common Stock

Jan 24, 2024, 8:35 AM EST - 1 year ago

Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products

Dec 18, 2023, 9:39 AM EST - 1 year ago

Immix Biopharma Announces Dr. Marko Radic, Autoimmune CAR-T Pioneer and Associate Professor at the University of Tennessee Health Science Center, Joins Scientific Advisory Board

$Immix Biopharma Announces 100% Overall Response Rate (n=10); 23.7 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2023$

Dec 11, 2023, 9:36 AM EST - 1 year ago

Immix Biopharma Announces 100% Overall Response Rate (n=10); 23.7 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2023

Dec 3, 2023, 2:02 AM EST - 1 year ago

Immix Biopharma: Seeking Catalysts To Propel Out Of Microcap Status

Nov 30, 2023, 9:46 AM EST - 1 year ago

Immix Biopharma to Present at the 2023 JMP Securities Hematology and Oncology Summit

$Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis$

Nov 22, 2023, 9:19 AM EST - 1 year ago

Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis

Nov 21, 2023, 9:46 AM EST - 1 year ago

Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing

$Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 9 Relapsed/Refractory AL Amyloidosis Patients$

Nov 6, 2023, 9:12 AM EST - 1 year ago

Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 9 Relapsed/Refractory AL Amyloidosis Patients

$Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 63 Relapsed/Refractory Multiple Myeloma Patients$

Nov 6, 2023, 8:40 AM EST - 1 year ago

Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 63 Relapsed/Refractory Multiple Myeloma Patients

Oct 26, 2023, 8:58 AM EDT - 1 year ago

Immix Biopharma Subsidiary Nexcella Announces Dr. Michaela Liedtke, Stanford Medicine Cancer Center Hematology Program Lead and Co-Director Stanford Amyloid Center, Joins Scientific Advisory Board

Oct 16, 2023, 9:05 AM EDT - 1 year ago

Immix Biopharma Completes 3rd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site

$Immix Biopharma Announces Complete Response in 9th Relapsed/Refractory AL Amyloidosis Patient in NXC-201 Clinical Trial at IMS 20th Annual Meeting$

Oct 3, 2023, 9:14 AM EDT - 1 year ago

Immix Biopharma Announces Complete Response in 9th Relapsed/Refractory AL Amyloidosis Patient in NXC-201 Clinical Trial at IMS 20th Annual Meeting

Oct 2, 2023, 8:06 AM EDT - 1 year ago

Immix Biopharma Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma

Sep 21, 2023, 8:55 AM EDT - 2 years ago

U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Amyloid Light Chain (AL) Amyloidosis

Sep 19, 2023, 9:10 AM EDT - 2 years ago

Immix Biopharma Subsidiary Nexcella Completes 2nd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site

Sep 19, 2023, 7:00 AM EDT - 2 years ago

Immix Biopharma: A Mid-To-Late Stage CAR-T Biotech Quietly Gaining Momentum

Sep 1, 2023, 8:39 AM EDT - 2 years ago

Immix Biopharma Announces Dr. Suzanne Lentzsch, Director of the Multiple Myeloma and Amyloidosis Program at the College of Physicians and Surgeons of Columbia University and at New York Presbyterian Hospital in New York, Joins Scientific Advisory Board

Aug 23, 2023, 8:37 AM EDT - 2 years ago

U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Multiple Myeloma

Dingalingading Jul. 29 at 8:01 PM

$IMMX

0 · Reply

keebs107 Jul. 29 at 4:19 PM

$IMMX

0 · Reply

ruck_my_life Jul. 29 at 9:00 AM

$IMMX Interesting. .

0 · Reply

keebs107 Jul. 28 at 6:42 PM

$IMMX

0 · Reply

RayIngersoll776 Jul. 28 at 3:01 PM

$IMMX works in oncology, but AITX is the one drawing eyes with a Palantir-level growth rate at an Apple-level valuation.

0 · Reply

keebs107 Jul. 24 at 7:29 PM

$IMMX

0 · Reply

PMtrader_92 Jul. 24 at 6:03 PM

$IMMX 🖕

0 · Reply

Dingalingading Jul. 24 at 1:05 PM

0 · Reply

Stocks4thought Jul. 23 at 6:11 PM

$IMMX Super pent up overhang- thought we'd erased it- but there you saw its exhausting $3.20 going to > $4 now- in about 3 weeks or less. $SLNO

0 · Reply

keebs107 Jul. 23 at 6:04 PM

$IMMX

0 · Reply

PMtrader_92 Jul. 23 at 3:41 PM

$IMMX lots of volume today😶‍🌫️

0 · Reply

Clubowner Jul. 23 at 2:20 AM

$IMMX seems like good risk reward here. great data. partnership is inevitable maybe even a buyout. partnership 2x buyout 5x. staying long

0 · Reply

Shadow2_6 Jul. 22 at 7:09 PM

$IMMX

0 · Reply

keebs107 Jul. 22 at 7:03 PM

$IMMX

0 · Reply

Dingalingading Jul. 22 at 6:17 PM

$IMMX

0 · Reply

Stocks4thought Jul. 22 at 4:44 PM

$IMMX Israel stocks - always skittish. Market of makers- not our creator- these are guys in hell- just mucking with the price $3.11 shortly.

0 · Reply

Stocks4thought Jul. 21 at 5:58 PM

$IMMX ( getting rid of trader skittish- and bad price performance- once used in the rear- view mirror. $7 move in the process- slow boat to China- but we will be there- data is to dam good) Stocks4thought Jul 18, 2025 10:16 AM $SLDB ot $IMMX another acid trip= ts a win $3 by Monday latest= This is a major win for Immix Biopharma. The data is highly promising and, if confirmed in a larger cohort, could position NXC-201 as a first-in-class, practice-changing therapy for R/R AL Amyloidosis. ot

0 · Reply

PMtrader_92 Jul. 21 at 1:12 PM

$IMMX 10 day obv 755,957

0 · Reply

Wise4Life2Rock Jul. 21 at 3:33 AM

💥 $ZENA $DPRO $BBAI $KSCP $IMMX 🚀

0 · Reply

Stocks4thought Jul. 18 at 5:16 PM

$SLDB ot $IMMX another acid trip= ts a win $3 by Monday latest= This is a major win for Immix Biopharma. The data is highly promising and, if confirmed in a larger cohort, could position NXC-201 as a first-in-class, practice-changing therapy for R/R AL Amyloidosis. ot

0 · Reply

Stocks4thought Jul. 18 at 3:52 PM

$ATYR We told you everyone loves $^6===============ot $SLNO $IMMX $STOK $TCRX

0 · Reply

Bionco Jul. 17 at 9:13 AM

$IMMX just got doubled and still holding

1 · Reply

Market Cap	75.83M
Revenue (ttm)	0.00
Net Income (ttm)	-21.61M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	181,000
Avg Vol	329,688
Day's Range	N/A - N/A
Shares Out	27.88M
Stochastic %K	4%
Beta	0.24
Analysts	Strong Sell
Price Target	$7.00